Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

By sjmartinez • July 28, 2024

Fleischmann R, Meerwein S, Charles-Schoeman C, Combe B, Hall S, Khan N, Carter KM, Camp HS, Rubbert-Roth A. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD Open. 2024 Jul 25;10(3):e003918. doi: 10.1136/rmdopen-2023-003918. PMID: 39059811; PMCID: PMC11284939.

Tags: Antirheumatic Agents, Publications, Rheumatoid arthritis, Rheumatology, Therapeutics

Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV

Zanni MV, Umbleja T, Fichtenbaum CJ, Fitch KV, McCallum S, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Schnittman SR, Erlandson KM, Diggs[...]

Social genomics, cognition, and well-being during the COVID-19 pandemic

Bateman JR, Krishnamurthy S, Quillen EE, Waugh CE, Kershaw KN, Lockhart SN, Hughes TM, Seeman TE, Cole SW, Craft S. Social genomics, cognition, and well-being[...]

Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT

Finn RS, Qin S, Piscaglia F, Evans TRJ, Knox JJ, López López C, Ramji Z, Ren M, Mody K, Vogel A, Kudo M. Characterization of[...]